TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: high-risk adenoma (HRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: pain (VAS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak blood alcohol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to peak blood alcohol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alcohol-related stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol-related sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dose to parotid glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dose to oral cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective delivery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protection against detrimental effects of UV on cutaneous immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity of sentinel lymph node identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of sentinel lymph node identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False-negative rate in sentinel lymph node biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the number of comedones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emesis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regurgitation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: everyday task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of blood transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change from baseline in the FSWB Scale overall score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time until discharge after endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of satisfaction with endoscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Paradoxical responses
Endpoint domain: Adverse events/effects
Primary endpoint: 2-h postprandial PG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of patient-recorded hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: CZ transversal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial impedance reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: roll-off delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in pruritus visual analog scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Eczema Area and Severity Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TGF-beta mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Durable reduction in motor complications (dyskinesia and OFF time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of vitamin C deficiency and hypovitaminosis C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achieving and maintaining normal or elevated vitamin C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diabetes distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durable bond strength to zirconia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental aspects of SF-8
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction with the nurse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk of AKI in CIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Left ventricular ejection fraction (LVEF) <50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resting sinus tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low cardiorespiratory fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage change in Oswestry Disability Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in supine blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AMH errors per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity-weighted AMH error scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMO errors per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of sight-threatening diabetic retinopathy (DR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Prevalence of diabetes without regular diabetic retinopathy control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year cumulative incidence of gallstone
Endpoint domain: Adverse events/effects
Primary endpoint: Weight of the uterine specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesia use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effectiveness of interventions for hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in schizophrenia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in Brief Psychiatric Rating Scale total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: W reactions to SP and CGRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F reactions to SP and CGRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treadmill walking time until moderate angina (P2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of OH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeat revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Curative effect of Herba Houttuyniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of reporting of CONSORT RCT abstract checklist questions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: declarative memory improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: reduction of ACTH and cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean tissue concentration of vancomycin in bones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with the format
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ability to express their views
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: perception that they contributed meaningfully to the process
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Head impacts/Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Yo-YoIR2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin mass (Hb(mass))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depressive symptom score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Partner psychological aggression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of right ventricular pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stability rating
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Montgomery‐Åsberg Depression Rating Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: louse-free rate
Endpoint domain: Mortality/survival
Primary endpoint: onset time at laryngeal adductor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-fatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: decrease in uterine artery PI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: reduction of elevated uterine impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: time spent reviewing client progress
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: time spent sending reminders to youth/families
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: shared agreement on tasks on the measure of working alliance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knee pain mitigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Range of motion of knees
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean whole mouth TMQHPI plaque scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractalkine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of CD11a (+) lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absent myocardial perfusion (MBG 0/1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absent STR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients achieving visual acuity of 20/30 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of 3 or more lines from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall tolerance of biopsy positions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for premedication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Somatic reactions during biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance with injections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: annual risk of falls
Endpoint domain: Mortality/survival
Primary endpoint: Proximal translation of sockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant effects on cardiac electrophysiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Identification of psychosocial concerns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of family violence concerns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attainment of vitamin D sufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TSH concentrations after rhTSH administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: leadership scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: MPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: D-dimer as a predictor of coronary risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: restoration of restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in hip BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decline in lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Achieving VL ≤50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical complication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: disease free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Fugl‐Meyer motor assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Adherence to supplementation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Return to spontaneous rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postdischarge fracture risk
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery of heart rate over 1 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean uterine leiomyomas size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean percentage time at pH 3 or above
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage time at pH 4 or above
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost of nursing time and supplies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dairy ARFS sub-category improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Activation Measure (PAM-13)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: diastolic blood pressure (dBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean blood pressure (mBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean urine protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of bipolar episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of in-hospital myocardial infarction or death
Endpoint domain: Mortality/survival
Primary endpoint: Menstrual pain intensity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: communication skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sevoflurane end-tidal concentration requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient withdrawal rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient medication rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: deterioration of self‐rated health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: dependence in ADLs
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in ACT total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Range of Motion (CROM) restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak TIPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BM response at 3-month post-treatment assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: BM progression
Endpoint domain: Mortality/survival
Primary endpoint: Deaths due to BM progression and extracranial disease progression
Endpoint domain: Mortality/survival
Primary endpoint: LV recovery at 3-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: in-hospital adverse cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in PEC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ACES score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician-diagnosed heart disease
Endpoint domain: Mortality/survival
Primary endpoint: Total walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usual walking for exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of contrast medium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: DLQI scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pruritus VAS scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SF-36 mental component summary scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of postoperative medications used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Left heart failure occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular extrasystoles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ankle dorsiflexion during swing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: foot clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial heel contact normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to reach 1500 g
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to regain birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Recall score decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraocular pressure (IOP) at trough drug effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Intraocular pressure (IOP) at peak drug effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Frequency of allergic conjunctivitis
Endpoint domain: Adverse events/effects
Primary endpoint: FTY720 maximum concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUC(0‐t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean lymphocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nutrient target goals met
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUROC improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Processing speed per image slice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidences of arrhythmia, shivering, nausea, and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Nausea and Vomiting (NV) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of myocardial enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Late G3/4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Median IFP decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of variceal rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pyrexia during treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Median time to onset of first pyrexia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median duration of pyrexia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of skin self-examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of wearing a shirt with long sleeves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Temperature ≥38°C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fussiness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total meperidine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: circumference measurements (abdominal, waist, hip)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-rated improvements in hyperactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-rated improvements in inappropriate speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of soft tissue anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes